Health Press Release – Newsletter for March 11, 2011

Sir Paul McCartney Supports BUAV Campaign to end Cruel Cosmetics Tests on Animals

LONDON, March 10, 2011 – Sir Paul McCartney has declared his support for BUAV's No Cruel Cosmetics
campaign to end animal testing for toiletries and cosmetic products sold in
the EU.

Sir Paul said: "Animals should not suffer in the name of beauty. Testing
toiletries and cosmetics on animals is cruel and unnecessary. Join … Read more : Sir Paul McCartney Supports BUAV Campaign to end Cruel Cosmetics Tests on Animals.

Web Perspectives Finds Most Canadian Respondents Resolved to go on a Health Kick This New Year

LONDON, March 10, 2011 – Web Perspectives, a leading online surveys website, has revealed that
respondents of its poll are resolved to making 2011 a healthier year than
2010. The answers to a recent survey asking the question, "What are your New
Year's resolutions?" showed that a good proportion of Canadian respondents
(18%) wanted to save money. However, …. Source  : Web Perspectives Finds Most Canadian Respondents Resolved to go on a Health Kick This New Year.

Agendia Hires David Macdonald as Chief Operating Officer, Mark Willig as Executive VP of North American Sales, and Doug Bradley as Vice President of Global Marketing

IRVINE, California and AMSTERDAM, March 10, 2011 – Agendia, a world leader in molecular cancer diagnostics, today
announced the hiring of David Macdonald as the company's Chief Operating
Officer, Mark Willig as Executive Vice President of North American Sales, and
Doug Bradley as Vice President of Global Marketing. Macdonald has been with
Agendia for the past eight months …. Original article  : Agendia Hires David Macdonald as Chief Operating Officer, Mark Willig as Executive VP of North American Sales, and Doug Bradley as Vice President of Global Marketing.

Exenatide Once Monthly Showed Positive Results in Phase 2 Study

BASINGSTOKE, England, March 10, 2011 – Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE:
LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced positive results from
a phase 2 study evaluating the effects of a once-monthly injectable
suspension formulation of exenatide on glycaemic control in patients with
type 2 diabetes.

The 121-patient phase 2 … Read : Exenatide Once Monthly Showed Positive Results in Phase 2 Study.

Lung Imaging Company Sets its Sights on Tackling COPD

MANCHESTER, England, March 10, 2011 – www.bioxydyn.com

A unique, non-invasive magnetic imaging (MRI) tool is being
developed by The University of Manchester (www.manchester.ac.uk/)
spinout company Bioxydyn (www.bioxydyn.com/). It has the potential to
considerably improve the treatment of lung conditions such as chronic
obstructive pulmonary disease (COPD), asthma, cystic fibrosis and emphasema
as well as aiding cancer …. Source  : Gaea News Network.